drugset / Trial / NCT03563248
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Phase 2
Active not recruiting
168 enrolled
Massachusetts General Hospital
Bristol-Myers Squibb · collabLustgarten Foundation · collabStand Up To Cancer · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: * FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Losartan * Nivolumab * Radiation Therapy * Surgery
Timeline
- Start
- 2018-08-10
- Primary completion
- 2022-02-16
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Losartan | Other / unclassified | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Background | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 1200 mg/m2 | Intravenous |